Literature DB >> 21612930

Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Ali Azhdarinia1, Nathaniel Wilganowski, Holly Robinson, Pradip Ghosh, Sunkuk Kwon, Zawaunyka W Lazard, Alan R Davis, Elizabeth Olmsted-Davis, Eva M Sevick-Muraca.   

Abstract

Optical imaging possesses similar sensitivity to nuclear imaging and has led to the emergence of multimodal approaches with dual-labeled nuclear/near-infrared (NIR) agents. The growing impact of (68)Ga (t(1/2)=68 min) labeled peptides on preclinical and clinical research offers a promising opportunity to merge the high spatial resolution of NIR imaging with the clinically-accepted positron emission tomography (PET). Previously, dual-labeled agents have been prepared with longer-lived radiometals and showed no detrimental effects on optical properties as a result of radiolabeling. In this study, we selected a peptide (M(2)) that targets MMP-2/9 and is dual-labeled with IRDye 800 CW and (68)Ga. Since (68)Ga chelation typically requires low pH (3.5-4) and elevated heating temperatures (95 °C), we sought to evaluate the impact of (68)Ga labeling on the optical properties of M(2). An efficient method for preparation of (68)Ga-M(2) was developed and reaction conditions were optimized. Stability studies in PBS, DTPA, and serum were performed and high levels of intact agent were evident under each condition. The addition of multiple reporters to a targeting agent adds further complexity to the characterization and validation and thus requires not only testing to ensure the agent is stable chemically and radiochemically, but also optically. Therefore, fluorescence properties were evaluated using a spectrofluorometer as well as by fluorescence detection via HPLC. It was determined that (68)Ga-labeling conditions did not impair the fluorescent properties of the agent. The agent was then used for in vivo imaging in a mouse model of heterotopic ossification (HO) with activated MMP-9 expression as an early biomarker which precedes mineralization. Although (68)Ga-complexation greatly reduced binding affinity of the peptide and negated tracer uptake on PET, NIR imaging showed consistent fluorescent signal that correlated to MMP-9 expression. This attests to the feasibility of using (68)Ga/NIR for dual-labeling of other peptides or small molecules for multimodality molecular imaging.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612930      PMCID: PMC3148023          DOI: 10.1016/j.bmc.2011.04.054

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  42 in total

1.  Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe.

Authors:  Chun Li; Wei Wang; Qingping Wu; Shi Ke; Jessica Houston; Eva Sevick-Muraca; Liang Dong; Diana Chow; Chusilp Charnsangavej; Juri G Gelovani
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

2.  Phage display peptide probes for imaging early response to bevacizumab treatment.

Authors:  Qizhen Cao; Shuanglong Liu; Gang Niu; Kai Chen; Yongjun Yan; Zhaofei Liu; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-16       Impact factor: 3.520

3.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

Review 4.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

5.  Association between markers of emphysema and more severe chronic obstructive pulmonary disease.

Authors:  P Boschetto; S Quintavalle; E Zeni; S Leprotti; A Potena; L Ballerin; A Papi; G Palladini; M Luisetti; L Annovazzi; P Iadarola; E De Rosa; L M Fabbri; C E Mapp
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

Review 6.  Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.

Authors:  M E Muroski; M D Roycik; R G Newcomer; P E Van den Steen; G Opdenakker; H R Monroe; Z J Sahab; Q-X Sang
Journal:  Curr Pharm Biotechnol       Date:  2008-02       Impact factor: 2.837

Review 7.  PET/CT for the staging and follow-up of patients with malignancies.

Authors:  T D Poeppel; B J Krause; T A Heusner; C Boy; A Bockisch; G Antoch
Journal:  Eur J Radiol       Date:  2009-04-29       Impact factor: 3.528

8.  Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light.

Authors:  Eiichi Tanaka; Hak Soo Choi; Valerie Humblet; Shunsuke Ohnishi; Rita G Laurence; John V Frangioni
Journal:  Surgery       Date:  2008-05-27       Impact factor: 3.982

9.  Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Authors:  Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

Review 10.  Near infrared fluorescent optical imaging for nodal staging.

Authors:  Lakshmi Sampath; Wei Wang; Eva M Sevick-Muraca
Journal:  J Biomed Opt       Date:  2008 Jul-Aug       Impact factor: 3.170

View more
  14 in total

Review 1.  Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability?

Authors:  Sven Hermann; Andrea Starsichova; Bianca Waschkau; Michael Kuhlmann; Christian Wenning; Otmar Schober; Michael Schäfers
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

Review 2.  Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.

Authors:  S Lütje; M Rijpkema; W Helfrich; W J G Oyen; O C Boerman
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

3.  Development of a Cell-Based Gene Therapy Approach to Selectively Turn Off Bone Formation.

Authors:  Pedro Alvarez-Urena; Banghe Zhu; Gabrielle Henslee; Corinne Sonnet; Eleanor Davis; Eva Sevick-Muraca; Alan Davis; Elizabeth Olmsted-Davis
Journal:  J Cell Biochem       Date:  2017-07-31       Impact factor: 4.429

4.  Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.

Authors:  Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  J Biomed Opt       Date:  2013-10       Impact factor: 3.170

5.  An Activatable NIR Fluorescent Rosol for Selectively Imaging Nitroreductase Activity.

Authors:  Jessica L Klockow; Kenneth S Hettie; Edward L LaGory; Eui Jung Moon; Amato J Giaccia; Edward E Graves; Frederick T Chin
Journal:  Sens Actuators B Chem       Date:  2019-11-30       Impact factor: 7.460

6.  Dual-modal in vivo fluorescence and photoacoustic imaging using a heterodimeric peptide.

Authors:  Jing Chen; Zhenghong Gao; Gaoming Li; Thomas D Wang
Journal:  Chem Commun (Camb)       Date:  2018-11-22       Impact factor: 6.222

Review 7.  Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.

Authors:  Ali Azhdarinia; Pradip Ghosh; Sukhen Ghosh; Nathaniel Wilganowski; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

Review 8.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 9.  Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.

Authors:  Chongwei Chi; Yang Du; Jinzuo Ye; Deqiang Kou; Jingdan Qiu; Jiandong Wang; Jie Tian; Xiaoyuan Chen
Journal:  Theranostics       Date:  2014-08-15       Impact factor: 11.556

Review 10.  Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development.

Authors:  Uwe Seibold; Björn Wängler; Ralf Schirrmacher; Carmen Wängler
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.